According to Ethel Branch, her son Patro still struggles with the lingering effects of RSV. He still experiences aftereffects, and the experience made her realize just how important RSV immunizations and education are in tribal communities. In May 2023 the U.S. Food and Drug Administration approved the first two RSV vaccines for adults. Then, in July 2023, the agency approved the first single-dose monoclonal antibody for RSV in infants, nirsevimab, which helps prevent severe illness and hospitalization. The RSV vaccines came too late for her—by mere months.